“Abemaciclib in real clinical practice of adjuvant therapy of HR+/HER2- high-risk breast cancer: experience of centers in Moscow”, Вопр. онкол., vol. 71, no. 3, p. OF-2319, Jun. 2025, doi: 10.37469/0507-3758-2025-71-3-OF-2319.